Aegle’s platform product has the potential to treat indications in a number of therapeutic areas. In addition to DEB and burns, we are evaluating a number of other severe dermatological rare diseases associated with genetic protein deficiencies. Additionally, Aegle believes its EV therapy can be used to treat surgical wounds, graft sites, scar revision, acute wounds and other dermatological indications. Aegle’s EV product AGLE-102 is currently administered both topically and as a local area injection.

Preclinical animal models have produced compelling data supporting the use of EVs for Graft vs. Host Disease prophylaxis. We believe EVs also have potential in inflammatory bowel diseases such as Crohn’s Disease. In CNS, Aegle believes that EVs have potential in the treatment of hemorrhagic stroke and traumatic brain injury. Other potential therapeutic areas include pulmonary, ophthalmology, and orthopedic where MSCs have shown efficacy in clinical trials. Aegle is evaluating the merits of pursuing these potential therapeutic areas before selecting its next indication.